Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has submitted a
New Drug Application (NDA) to the U.S. Food and Drug Administration
(FDA) for marketing approval of cobicistat, a pharmacoenhancing or
"boosting" agent that increases blood levels of certain commercially
available protease inhibitors, including atazanavir and darunavir, in
order to enable once-daily dosing. Cobicistat is also a component of the
Quad once-daily single tablet regimen for HIV, which is currently under
U.S. and European regulatory review for treatment-naïve adult patients.
"With today's filing, Gilead's series of U.S. and European regulatory
filings for the Quad and its investigational components is complete,"
said Norbert Bischofberger, PhD, Executive Vice President, Research and
Development and Chief Scientific Officer, Gilead Sciences. "We will
continue to work with regulatory authorities to bring these important
new therapies to people living with HIV."
The NDA for cobicistat is supported by 48-week data from a pivotal Phase
3 study (Study 114) in which cobicistat met its primary objective of
non-inferiority to ritonavir when both agents were administered with a
background regimen of atazanavir sulfate plus Truvada®
(emtricitabine and tenofovir disoproxil fumarate). The NDA is also
supported by pharmacokinetic data demonstrating that cobicistat boosts
blood levels of atazanavir and darunavir similar to ritonavir.
Gilead entered into an agreement with Janssen R&D Ireland in June 2011
for the development of a fixed-dose combination of cobicistat and
darunavir. In October 2011, Gilead announced an agreement with
Bristol-Myers Squibb to develop a fixed-dose combination of cobicistat
and atazanavir. Subject to regulatory approval, Janssen and
Bristol-Myers Squibb will be responsible for the formulation,
manufacturing, registration, distribution and worldwide
commercialization of the cobicistat and darunavir fixed-dose combination
and the cobicistat and atazanavir fixed-dose combination, respectively.
Study shows safety of kidney transplants among those with HIV infections